What is the recommended immunization schedule for patients without a functional spleen (asplenic)?

Immunization Schedule for Asplenic Patients

Asplenic patients require a specific vaccination protocol centered on protection against encapsulated bacteria, with pneumococcal (PCV13/PCV15/PCV20 followed by PPSV23), meningococcal (MenACWY and MenB), Haemophilus influenzae type b (Hib), and annual influenza vaccines as the core components. 1

Core Vaccine Requirements

Pneumococcal Vaccination

For patients ≥2 years old:

• Administer PCV13 (or newer PCV15/PCV20) first
• Follow with PPSV23 at least 8 weeks after PCV13 2, 1
• Give a second dose of PPSV23 five years after the first PPSV23 dose 1
• For patients ≥65 years who received PPSV23 before age 65, give another dose if ≥5 years have passed 2

Timing considerations:

• For elective splenectomy: vaccinate ≥2 weeks before surgery (strong recommendation) 1
• For emergency splenectomy: vaccinate ≥2 weeks after surgery 1
• Vaccinating before 14 days post-splenectomy yields suboptimal antibody response 3

Meningococcal Vaccination

Administer 2 doses of MenACWY at least 2 months apart 2

• Revaccinate every 5 years for ongoing risk 1
• Add MenB vaccine series (2 or 3 doses depending on formulation) for patients ≥2 months 1
• MenB boosters: one dose at 1 year, then every 2-3 years if risk persists 4

Critical caveat: Do not give MCV4-D to children <2 years when PCV is also needed, as it reduces pneumococcal antibody response 1

Haemophilus Influenzae Type b (Hib)

One dose for unvaccinated persons ≥5 years who are asplenic 1

• Children <2 years should receive Hib per routine childhood schedule 1

Influenza Vaccination

Annual inactivated influenza vaccine for all asplenic patients 5, 3

• Influenza increases risk of secondary bacterial infections, particularly pneumococcal 5, 3
• Live attenuated influenza vaccine (LAIV) is contraindicated 1

Additional Recommended Vaccines

Standard Adult Vaccines

• Tetanus-diphtheria-pertussis (Tdap/Td) per routine schedule
• MMR and varicella if no evidence of immunity (not contraindicated in asplenia) 1
• Hepatitis A and B based on standard risk factors
• HPV for patients ≤26 years (can consider up to age 45) 4
• Recombinant zoster vaccine (RZV) for patients ≥50 years or ≥18 years at increased risk 4

Critical Implementation Points

Timing Algorithm

For elective splenectomy:

1. Complete all vaccinations ≥2 weeks before surgery 1, 3
2. This ensures optimal antibody response

For emergency/traumatic splenectomy:

1. Wait until ≥14 days post-surgery for vaccination 3
2. Exception: If high risk of loss to follow-up, vaccinate before discharge even if <14 days 3
3. The earlier after 14 days, the better 3

Common Pitfalls to Avoid

1. Wrong vaccine sequence: Always give PCV13/15/20 before PPSV23, never reverse this order 2, 1
2. Insufficient interval: The 8-week minimum between PCV and PPSV23 is critical for optimal response 2, 1
3. Missing revaccination: PPSV23 needs a second dose at 5 years; meningococcal vaccines need boosters every 5 years 2, 1
4. Forgetting MenB: Many protocols only mention MenACWY, but MenB is equally important 1
5. Premature vaccination post-splenectomy: Vaccinating before 14 days yields suboptimal response 3

Antibiotic Prophylaxis

Lifelong prophylactic antibiotics should be offered, especially in the first 2 years post-splenectomy 6

• Phenoxymethylpenicillin is standard
• Erythromycin for penicillin-allergic patients 6
• Patients should have emergency antibiotic supply (amoxicillin 3g starting dose, then 1g every 8 hours) for sudden fever or illness 3

Patient Education Requirements

• Inform patients that vaccination reduces but does not eliminate OPSI risk 3
• Vaccines cover only 23 of 90 pneumococcal serotypes 3
• Risk of overwhelming infection is highest in first 2 years but remains lifelong 3, 6
• Mortality from OPSI ranges 30-70%, with most deaths in first 24 hours 3
• Patients need medical alert identification and should inform all healthcare providers 3, 6

Special Populations

**Children <5 years:** Higher infection risk (>10% vs <1% in adults), may need reimmunization as early as 3 years, especially with sickle cell disease 6

Immunocompromised patients: May have inadequate antibody response; consider additional PCV dose instead of PPSV23 in chronic GVHD 4

The evidence strongly supports this comprehensive vaccination approach, with the 2013 IDSA guidelines 1 providing the most detailed and authoritative recommendations, reinforced by multiple national immunization schedules 2.